Depressive disorder
Conditions
Interventions
Trial Group:Conventional drug therapy (sertraline 50-100mg qd) + oral vitamin D2 soft capsules (every 2 days, 1 capsule each time, specification 0.125mg/5000 IU)
Control Group:Conventional drug therapy (sertraline 50-100mg qd) + oral placebo (gelatin hollow capsules, every 2 days, 1 capsule each time)
Sponsors
Southern Medical University Southern Hospital
Eligibility
Sex/Gender
All
Age
12 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1.The age must satisfy >=12 years old and 17 points, DSRSC score >15 points; 6.With the informed consent of the subjects and their legal guardians, voluntary participation, and the signing of the informed consent form;
Exclusion criteria
Exclusion criteria: 1.Comorbid with other mental disorders (e.g., bipolar disorder, schizophrenia, etc.); 2.Renal dysfunction, hypercalcemia, hyperphosphatemia; 3.Diagnosis of hypoparathyroidism or hyperparathyroidism; 4.Comorbid with severe physical illnesses or organic brain diseases;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in Hamilton Depression Rating Scale 17-item (HAMD-17) score from baseline to week 4 after the start of intervention;Change in HAMD-17 score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in PSQI score;Change in HAMA score;Change in DSRSC score;The marked efficacy from baseline to the 2nd and 4th weeks after the intervention began (marked efficacy was defined as a decrease of > =50% in the total score of HAMD-17 at the end of the 2nd week compared to the baseline total score of HAMD-17);Change in MEQ-5 score; | — |
Countries
China
Contacts
Public ContactLuo Xian
Southern Medical University Southern Hospital
Outcome results
None listed